T 1168/24 (Lipid formulations for nucleic acid delivery/ARBUTUS BIOPHARMA CORPORATION) of 15.01.2026
- European Case Law Identifier
- ECLI:EP:BA:2026:T116824.20260115
- Date of decision
- 15 January 2026
- Case number
- T 1168/24
- Online on
- 18 June 2026
- Petition for review of
- -
- Application number
- 09731866.1
- Language of proceedings
- English
- Distribution
- Distributed to board chairmen (C)
- Download
- Decision in English
- OJ versions
- No OJ links found
- Other decisions for this case
- -
- Abstracts for this decision
- -
- Application title
- Novel lipid formulations for nucleic acid delivery
- Applicant name
- Arbutus Biopharma Corporation
- Opponent name
- Merck Sharp & Dohme LLC
ModernaTX, Inc. - Board
- 3.3.08
- Headnote
- -
- Relevant legal provisions
- European Patent Convention Art 123(2)European Patent Convention R 101(1)European Patent Convention R 106European Patent Convention R 139Rules of procedure of the Boards of Appeal Art 13(2)
- Keywords
- Correction of error - (yes)
Admissibility of appeal - (yes)
Amendments - added subject-matter (yes)
Amendment to a party's appeal case - cogent reasons (no) - Catchword
- See Reasons 12 to 34 for a discussion of the applicability of the principle of the prohibition of reformatio in peius
- Cited cases
- G 0009/92G 0001/99G 0001/12T 0724/99T 0972/04T 1194/06T 1843/09T 2086/13T 2129/14T 1621/16T 2635/18T 0727/19T 1442/19T 0505/20T 0974/21
- Citing cases
- -
Order
For these reasons it is decided that:
1. The appeal of opponent 2 is admissible.
2. The request to refer a question to the Enlarged Board of Appeal is rejected.
3. The proprietor's Rule 106 EPC objection is dismissed.
4. The decision under appeal is set aside.
5. The patent is revoked.